Pharmaceutical Venture Capital Firms
Welcome to VC Firms List, where we specialize in providing quality lists of venture capital firms across different industries. Today, we are focusing on an increasingly vital sector in the investment world: pharmaceutical venture capital firms. As the pharmaceutical industry continues its rapid growth, venture capitalist support plays a vital role in fostering innovation and development. Did you know, according to a report by Statista, global venture financing in biotech companies reached over $16 billion in 2020, indicating the market's enormous potential.
Read more
Company:
Linden Capital Partners
Description: Linden Capital Partners is a private equity firm based in Chicago that specializes in leveraged buyouts within the healthcare and life sciences sectors. The firm's investment strategy is anchored in three key elements: a focus on industry specialization in healthcare and life sciences, a blend of integrated private equity and operational expertise, and the cultivation of strategic relationships with large corporations. Linden Capital Partners concentrates its efforts on investing in middle-market platforms across various segments of the healthcare industry, including medical products, specialty distribution, pharmaceuticals, and related services. Through its dedicated approach, the firm aims to create value and foster growth in these vital sectors.
Industry: Venture Capital and Private Equity
Founded: 2002
Domain: http://www.lindenllc.com/
Location: Chicago, IL
Address: 110 N Wacker Drive, 5500, Chicago, IL 60606, US
Size: 11-50 employees
Company:
MVM Partners
Description: MVM Partners is a distinguished investment fund specializing in life sciences, with over 25 years of experience in the field. The firm engages in a wide range of opportunities across the healthcare sector, encompassing specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, contract manufacturing, healthcare services, and digital health. With a robust global perspective on healthcare, MVM Partners operates offices in both Boston and London, allowing them to maintain a keen awareness of emerging trends and innovations across diverse markets. The firm’s current portfolio includes companies headquartered in the United States and Europe, many of which have established extensive operations throughout the Middle East and Asia, further demonstrating MVM's commitment to fostering growth and innovation in the global healthcare landscape.
Industry: Venture Capital and Private Equity
Founded: 1997
Domain: http://www.mvm.com/
Location: 45 School Street, Boston MA
Address: MVM Partners, Old City Hall, 45 School Street, Boston MA 02108, US
Size: 11-50 employees
Company:
McKesson
Description: McKesson Corporation stands as a prominent leader in the global healthcare industry, committed to advancing health outcomes for individuals and communities around the world. As an impact-driven organization, McKesson plays a vital role in nearly every facet of healthcare delivery. The company collaborates with a diverse range of stakeholders—including biopharmaceutical companies, healthcare providers, pharmacies, manufacturers, and government entities—to provide valuable insights, products, and services that enhance the accessibility and affordability of quality care.
The leadership at McKesson fosters an environment where employees are encouraged to adopt a growth mindset, cultivating a culture of excellence that benefits customers, partners, and the overall well-being of people globally. The organization is dedicated to delivering improved health outcomes not only for its customers but also for its employees and the communities it serves. McKesson strives to inspire and empower individuals to achieve their full potential, making a positive impact on both public health and the environment.
To discover more about how McKesson and its team contribute to enhancing care across various settings, interested parties are invited to explore further information available at their official channels. Whether through innovative solutions or collaborative efforts, McKesson's commitment to bettering healthcare continues to resonate throughout the industry.
Industry: Hospitals and Health Care
Domain: http://www.mckesson.com/
Location: Irving, Texas
Address: 6555 State Highway 161, Irving, Texas 75039, US
Size: 10,001+ employees
Company:
Milestone Capital
Description: Milestone Capital is a distinguished venture capital and private equity firm that manages three US dollar private equity funds, primarily investing in well-established high-growth companies that are seeking expansion or acquisition capital in China. The firm’s objective is to maximize medium to long-term capital appreciation by making direct investments that allow for the acquisition of either minority or majority equity stakes in carefully selected companies. These companies are identified by Milestone Capital's experienced investment team, which is committed to recognizing potential for growth and success.
Milestone Capital boasts a strong track record of assisting portfolio companies in their pursuit of public listings on both domestic and international stock exchanges. By leveraging an extensive network of advisors, industry executives, and established business relationships, the firm provides comprehensive value-added support from both financial and strategic perspectives. This commitment enhances the operational capacities of portfolio companies, allowing them to navigate complex financial landscapes more effectively.
To date, Milestone Capital has successfully facilitated the public listing of ten of its portfolio companies on major overseas stock exchanges. Notably, in July 2005, Focus Media Holdings Limited (Ticker: FMCN) made its debut on the NASDAQ, followed by Trina Solar Limited (Ticker: TSL), which listed on the New York Stock Exchange in December 2006. VisionChina Media Inc. (Ticker: VISN) followed suit with a NASDAQ listing in December 2007. Additionally, GCL Silicon Technology Holdings Inc. became part of GCL-Poly Energy Holdings Limited (Ticker: 3800HK) through acquisition in April 2010. Other successful listings include Dehaier Medical Systems Limited (Ticker: DHRM) on the NASDAQ in July 2012, Xiao Nan Guo Restaurants Holdings Limited (Ticker: 3666HK) on the Hong Kong Stock Exchange (HKSE) in September 2013, and Tenwow International Holdings Limited (Ticker: 1219HK) on the HKSE in October 2013. Milestone Capital also facilitated the listing of Cabbeen Fashion Limited (Ticker: 2030HK) on the HKSE in September 2015 and JHL Biotech (Ticker: 6540TW) on the Emerging Stock Board of Taipei Exchange in June 2017, followed by Aslan Pharmaceuticals (Ticker: 6497), which listed on the Main Board of Taipei Exchange.
Through its strategic investments and support, Milestone Capital continues to solidify its reputation as a leader in the venture capital and private equity space, driving growth and value creation for its portfolio companies within the dynamic landscape of the Asian markets.
Industry: Venture Capital and Private Equity
Founded: 2002
Domain: http://www.mcmchina.com/
Location: 上海市, 上海市
Address: 湖南路, 上海市, 上海市 200031, CN
Size: 11-50 employees
Company:
Naples Technology Ventures
Description: Naples Technology Ventures (NTV) is a dedicated investment firm specializing in early-stage business-to-business (B2B) software as a service (SaaS) companies that demonstrate significant value in their respective markets. The firm actively seeks investment opportunities within sectors such as healthcare and insurance, industries that are currently poised for modernization and enhanced operational efficiency. These sectors have historically been slow to adapt, often relying on outdated legacy systems and entrenched manual processes. Consequently, there is a pressing need for innovative technologies that can streamline processes, eliminate operational silos, and foster greater scalability.
Additionally, Naples Technology Ventures seeks to invest in companies that deliver solutions tailored for regulated industries. As regulatory requirements and compliance mandates continue to evolve, firms within these sectors—including pharmaceuticals, healthcare, finance, aerospace, and defense—are increasingly tasked with enhancing their access to data, transparency, disclosures, and reporting. The ramifications of noncompliance in these industries can be significant, further emphasizing the necessity for effective solutions that facilitate compliance with regulatory obligations. NTV aims to support companies that provide tools capable of simplifying the regulatory compliance process.
The focus of Naples Technology Ventures is primarily on SaaS enterprises that leverage cutting-edge technologies such as artificial intelligence (AI), machine learning, blockchain, the Internet of Things (IoT), and robotics. In evaluating prospective investments, NTV places a strong emphasis on the quality of management teams, viewing them as essential contributors to a company’s success. The firm seeks to partner with experienced entrepreneurs who have a proven track record in launching successful businesses, recognizing that effective leadership is crucial for growth. Additionally, a deep understanding of company finances and the optimal use of sales and marketing teams is deemed vital for generating substantial growth.
Investment engagement primarily targets the Series Seed and Series A funding rounds, aligning with NTV’s commitment to supporting innovative companies at pivotal stages of their development. Through their strategic investments, Naples Technology Ventures is devoted to fostering the growth of companies that are primed to make significant strides within their industries.
Industry: Venture Capital and Private Equity
Location: Naples, Florida
Address: Naples, Florida, US
Size: 11-50 employees
Company:
ONCE Ventures
Description: ONCE Ventures, operating as the venture capital arm of Otsuka's Nutraceuticals division, is dedicated to fostering a healthier and more sustainable future by supporting visionary entrepreneurs and innovators. The firm focuses on investing in early-stage companies across North America that are at the forefront of innovation. These entrepreneurs share ONCE Ventures' commitment to improving health outcomes within the realms of Active Nutrition, Healthy Beverages, Plant-Based Foods, and Supplements.
The investment strategy of ONCE Ventures is straightforward yet effective: they seek to partner with early-stage companies that strive to enhance the well-being of their consumers. Through this partnership approach, ONCE Ventures leverages the extensive knowledge and capabilities of Otsuka to support and accelerate the growth of these companies.
For over a century, Otsuka has pursued its mission of building a healthier world through innovative and creative solutions. The Otsuka group comprises a global network of 180 companies, employing nearly 45,000 individuals and generating annual revenues of approximately $13 billion. Otsuka operates across 28 countries and regions in the Pharmaceuticals and Nutraceuticals sectors. Notable brands within Otsuka's global Nutraceuticals platform include POCARI SWEAT in Japan, Nature Made, MegaFood, and Daiya in the United States, as well as Nutrition Sant in Europe.
Throughout its evolution, Otsuka has maintained a strong commitment to its core identity and family-oriented roots. ONCE Ventures exemplifies this spirit by being a substantial venture capital entity that embraces unconventional thinking and challenges the status quo in pursuit of transformative health solutions.
Industry: Venture Capital and Private Equity
Founded: 2020
Domain: http://www.onceventures.com/
Location: Los Angeles, CA
Address: Los Angeles, CA, US
Size: 2-10 employees
Company:
Pandect Bioventures
Description: Pandect Bioventures is a distinguished venture capital firm that specializes in providing funding opportunities for early-stage biotech and pharmaceutical companies. Focusing on investments ranging from seed funding to Series A and beyond, Pandect Bioventures is dedicated to supporting innovative entrepreneurs in the life sciences sector. In addition to financial backing, the firm offers comprehensive management support, which is designed to assist these companies in navigating the complexities of their industry and achieving essential business milestones. Through its strategic approach and commitment to fostering growth, Pandect Bioventures plays a vital role in advancing the development of groundbreaking solutions in biotechnology and pharmaceuticals.
Industry: Venture Capital and Private Equity
Founded: 2018
Domain: http://www.pandectbio.com/
Location: South San Francisco, California
Address: 280 Utah Ave, South San Francisco, California 94080, US
Size: 2-10 employees
Company:
Pharmaron
Description: Pharmaron, trading under the stock codes 300759SZ and 3759HK, stands as a leading service provider within the life sciences industry. Established in 2004, Pharmaron has made significant investments in its personnel and facilities, resulting in the creation of a comprehensive suite of research, development, and manufacturing services. These capabilities span the entire drug discovery process, including preclinical and clinical development, and cater to a wide array of therapeutic modalities such as small molecules, biologics, and advanced cell and gene therapy (CGT) products.
With a workforce exceeding 20,000 employees, Pharmaron operates across multiple regions, including China, the United States, and the United Kingdom. The company has demonstrated a strong track record in providing research and development solutions to its partners throughout North America, Europe, Japan, and China.
Pharmaron offers an extensive range of services designed to support its clients through various stages of drug development. These services encompass synthetic medicinal and analytical chemistry, biology services, drug metabolism and pharmacokinetics (DMPK), pharmacology services, drug safety assessments, radiochemistry, and isotopically labeled metabolism services, as well as chemical and pharmaceutical development. In addition, Pharmaron provides clinical development services that aid in the progression of drug candidates through clinical trials.
The company’s capabilities also include specialized areas such as library synthesis, bioorganic chemistry, discovery process chemistry, radiolabeled chemical synthesis, and cheminformatics. Moreover, Pharmaron is equipped to handle in vitro and in vivo biology studies, animal disease models, pharmacokinetics (PK), and pharmacodynamics (PD), as well as quality assurance and regulatory affairs.
Pharmaron actively addresses various aspects of drug creation and assessment, including biopharmaceuticals and the manufacturing of active pharmaceutical ingredients (APIs). The organization excels in material science, formulation development, drug product manufacturing, toxicology, safety pharmacology, genetic toxicology, and pathology.
With a commitment to advancing scientific knowledge and meeting industry demands, Pharmaron continues to be a trusted partner in the life sciences sector, providing vital support throughout the drug development lifecycle. For more information, Pharmaron can be explored at www.pharmaron.com.
Industry: Pharmaceutical Manufacturing
Domain: http://www.pharmaron.com/
Location: Beijing
Address: 6 Taihe Road, BDA, Beijing, 100176, CN
Size: 10,001+ employees
Company:
Qiming Venture Partners
Description: Founded in 2006, Qiming Venture Partners has established itself as a prominent venture capital firm operating within the dynamic landscapes of both venture capital and private equity. With offices strategically situated in major cities such as Shanghai, Beijing, Suzhou, Hong Kong, and Singapore, Qiming Venture Partners is well-positioned to identify and support innovative companies across the Asia-Pacific region.
The firm currently manages a diverse portfolio comprising eleven U.S. Dollar funds and seven RMB funds, with a remarkable total of 95 billion in capital raised. Since its inception, Qiming Venture Partners has focused on investing in exceptional companies within the Technology and Consumer (TC) sectors, as well as the Healthcare industry, targeting businesses at both early and growth stages. Over the years, the firm has successfully backed more than 530 fast-growing and innovative enterprises, demonstrating a strong commitment to fostering entrepreneurial success.
A notable achievement for Qiming Venture Partners is that over 200 of its portfolio companies have accomplished successful exits through initial public offerings (IPOs) on prominent exchanges, including the New York Stock Exchange (NYSE), NASDAQ, Hong Kong Stock Exchange (HKEX), as well as the Shanghai and Shenzhen Stock Exchanges. Additionally, the firm has supported over 70 portfolio companies in reaching unicorn status, highlighting its ability to identify companies with significant growth potential.
Among its diverse portfolio, Qiming Venture Partners has backed some of the most influential firms in their respective sectors, including notable names such as Xiaomi (SEHK: 1810), Meituan (SEHK: 3690), Bilibili (NASDAQ: BILI), and Zhihu (NYSE: ZH), as well as Roborock (SHSE: 688169), Gan & Lee Pharmaceuticals (SHSE: 603087), and Tigermed (SZSE: 300347). The firm’s investments extend to other key players like Zai Lab (NASDAQ: ZLAB), CanSino Biologics (SEHK: 6185), Schrodinger (NASDAQ: SDGR), and New Horizon Health (SEHK: 6606), showcasing its far-reaching impact across various industries.
In addition to these well-known companies, Qiming Venture Partners has also supported emerging innovators such as Sanyou Medical (SHSE: 688085), AmoyDx (SZSE: 300685), Berry Genomics (SZSE: 000710), SinocellTech (SHSE: 688520), UBTech (SEHK: 9880), Yuanxin Technology, Caidya, Belief BioMed, WeRide, and Biren Technology, among many others. This extensive network of successful investments underscores Qiming Venture Partners' dedication to nurturing the next generation of trailblazing companies and their significant contributions to the economy and society at large.
Industry: Venture Capital and Private Equity
Founded: 2006
Domain: http://www.qimingvc.com/
Location: Hong Kong
Address: Room 3901 Jinmao Tower, 88 Century Boulevard, Hong Kong, HK
Size: 51-200 employees
Company:
Revelation Partners
Description: Revelation Partners is a prominent firm specializing in venture capital and private equity within the healthcare ecosystem. The company is dedicated to offering flexible capital solutions that cater to the unique needs of the industry. By providing liquidity for illiquid private holdings, Revelation Partners aims to eliminate barriers to investment and enhance growth opportunities for various stakeholders within the healthcare sector.
With a broad investment focus that spans all healthcare subsectors, including medical devices, life science tools and diagnostics, biopharmaceuticals, healthcare technology, and healthcare services, Revelation Partners demonstrates a comprehensive understanding of the diverse landscape of healthcare investment. The firm prides itself on its decades of investing experience, which is complemented by deep sector expertise and an extensive network within the industry.
Revelation Partners has successfully committed over $15 billion in capital, positioning itself as a trusted partner for healthcare investors, companies, and funds. Their commitment to innovation and collaboration enables them to support the growth of healthcare organizations, helping to drive advancements that benefit the broader ecosystem. Through their strategic approach and in-depth knowledge, Revelation Partners continues to be a key player in the healthcare investment space.
Industry: Venture Capital and Private Equity
Location: Sausalito, California
Address: 300 Turney St, Sausalito, California 94965, US
Size: 11-50 employees
Company:
RiverVest Venture Partners
Description: RiverVest Venture Partners stands out as a prominent venture capital firm that focuses on building life science companies aimed at addressing significant unmet patient needs while simultaneously delivering strong, consistent returns to investors. With its headquarters located in St. Louis and additional offices in San Diego and Cleveland, RiverVest strategically accesses innovative research and clinical expertise from leading institutions throughout the United States.
Entrepreneurs often turn to RiverVest for its comprehensive support, which encompasses scientific, operational, financial, and investment expertise critical for achieving long-term success in the competitive life sciences industry. The firm is dedicated to conducting business with the highest ethical standards, ensuring favorable outcomes for all stakeholders involved, including patients, entrepreneurs, and investors.
Since its inception in 2000, RiverVest has successfully funded over 60 innovative life science companies, demonstrating its commitment to fostering advancements that can improve healthcare outcomes. The firm currently manages approximately $750 million in assets, reflecting its significant role in the venture capital and private equity landscape. For more detailed information about their initiatives and investment strategies, interested parties are encouraged to visit their website at http://www.rivervest.com.
Industry: Venture Capital and Private Equity
Founded: 2000
Domain: http://www.rivervest.com/
Location: St. Louis, MO
Address: 101 S. Hanley Road, Suite 1850, St. Louis, MO 63105, US
Size: 11-50 employees
Company:
Sherpa Healthcare Partners (夏尔巴投资)
Description: Sherpa Healthcare Partners (夏尔巴投资) is a distinguished venture capital and private equity firm founded by a highly experienced team of entrepreneurs. This team is dedicated to investing in and nurturing the growth of the pharmaceutical and biotech industries. Sherpa Healthcare Partners specializes in identifying and managing investments in leading companies and innovative startups across various sectors, including pharmaceuticals, gene technology, medical technology, and healthcare services.
The firm has successfully established a robust portfolio that fosters enduring value, collaborative partnerships, and strong relationships within the industry. Their commitment to building lasting connections allows them to provide comprehensive, all-cycle services that leverage essential resources for their portfolio companies. With a core team boasting over 15 years of experience in healthcare investment operations and management, Sherpa Healthcare Partners operates with shared values and deep mutual trust. Their complementary expertise enables them to navigate the complexities of the healthcare landscape effectively, positioning them as a reputable player in the venture capital and private equity arena focused on healthcare innovation.
Industry: Venture Capital and Private Equity
Founded: 2018
Domain: http://www.sherpavc.com.cn/
Location: Beijing, Beijing
Address: A0410, 4/F, Unit A, Huibin Building, No. 8. Beichen East Road, Chaoyang District, Beijing, Beijing 100029, CN
Size: 2-10 employees
Company:
Source Code Capital
Description: Source Code Capital is dedicated to establishing itself as the preferred partner for exceptional entrepreneurs who are at the forefront of contemporary business transformations and technological advancements. Founded in 2014, Source Code Capital currently manages approximately RMB 35 billion in assets, encompassing both RMB and USD investments. The firm adheres to a bottom-up approach rooted in fundamental analysis and thorough research to inform their investment strategies.
Since its inception, Source Code Capital has actively focused on investments that promote technological innovation and development. The firm is committed to supporting small and midsized enterprises, enhancing the livelihoods of individuals, and fostering green development, among other significant initiatives. Over the years, Source Code Capital has formed partnerships with more than 300 companies across a wide array of sectors, including Industrial Digitization, Artificial Intelligence, Robotics, Advanced Manufacturing, Green Development, Enterprise Software, Healthcare and Biotech, New Consumption and New Brands, as well as Global ventures.
The portfolio of Source Code Capital features a diverse family of companies, including notable names such as Bytedance, Meituan, KE Holdings Inc., Li Auto, RELX Technology, and others. This extensive lineup illustrates the firm’s active role in various innovative domains. Their investments also encompass firms like Baibu, XiaoYaoYao, Casstime, Ruigushop, YQNLink, Yijiupi, and Zhongneng United, along with emerging technology companies such as Hai Robotics, Chuxin, MechMind Robotics, and Keenon.
Source Code Capital has shown a strong commitment to backing cutting-edge firms, including Niu Technologies, Biren Technology, Silicon Integrated, GalaxySpace, and many others across diverse fields such as energy, technology, and biotech. In particular, the firm has made notable investments in companies like Unisun Energy, POWER OAK, Cloudgoing Technology, and various others that exemplify pioneering advancement.
Additionally, Source Code Capital takes pride in its innovative initiative, Code Class, which is a proprietary industry super hub. This unique community comprises over 300 entrepreneurs and expands to encompass broader partnerships, all aimed at creating substantial value within the entrepreneurial ecosystem. Through these efforts, Source Code Capital continues to play a pivotal role in fortifying technological growth and fostering entrepreneurial success within the sector.
Industry: Venture Capital and Private Equity
Founded: 2014
LinkedIn: https://www.linkedin.com/company/源码资本
Domain: http://www.sourcecodecap.com/
Location: 北京, 北京
Address: 北京市朝阳区望京东园七区保利国际广场塔1，26层, 北京, 北京 100102, CN
Size: 51-200 employees
Company:
Takeda Digital Ventures
Description: Takeda Digital Ventures (TDV) serves as the corporate venture capital arm of Takeda Pharmaceutical Company, focusing on investment in the most promising Virtual First Care (V1C) companies. These companies leverage digital technologies to enhance outcomes and improve experiences throughout the patient journey. TDV is committed to investing solely in organizations that embrace a patient-first philosophy and reflect the core values of Takeda.
Operating on a global scale with a particular emphasis on North America and Europe, TDV's investment strategy encompasses a diverse range of entities—ranging from well-established firms to those with a minimal viable product that ideally demonstrates early commercial traction. The firm prioritizes the identification of innovative technologies that can effectively deliver value-based outcomes for patients, all while ensuring a seamless, convenient, and enjoyable experience.
In addition to its investment endeavors, TDV is driven by a mission within its Venture Studios to develop new companies across various therapeutic areas, each committed to providing targeted patient solutions through the use of digital capabilities. This reflects TDV's broader goal of enhancing patient care and experiences in the evolving healthcare landscape.
As the digital healthcare investment arm of one of the top ten global biopharmaceutical companies, an investment from Takeda Digital Ventures offers more than just financial support. Partners benefit from exclusive access to Takeda's extensive global expertise and are invited to participate in various portfolio innovation events. Within the Takeda ecosystem, TDV acts as a catalyst for fostering closer relationships and facilitating efficient business development outreach.
The team at Takeda Digital Ventures comprises seasoned professionals who have successfully guided numerous companies from seed funding stages to profitable exits. With a strong foundation of investment and operational expertise, TDV is supported by a world-class network of operational partners, digital healthcare specialists, and clinical trial advisors, all of whom contribute to the development of successful, impactful companies. Through a hands-on approach, they strive to add significant value to their portfolio companies, often taking board seats when appropriate to ensure strategic guidance and support.
Industry: Venture Capital and Private Equity
Founded: 2018
Location: Cambridge, MA
Address: 650 East Kendall Street, Cambridge, MA 02139, US
Size: 2-10 employees